Literature DB >> 22767340

A reduction in between subject variability is not mandatory for selecting a new covariate.

Chakradhar V Lagishetty1, Pavan Vajjah, Stephen B Duffull.   

Abstract

Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical modelling where the mean response in a population and the variability in response from different sources are studied. It generally consists of two model hierarchies: a model for residual error and a model for heterogeneity termed between subject variance (BSV). The overall variability in a parameter within a population termed population parameter variance (PPV) consists of within subject variance (WSV) and BSV. Both these variances can further be split into random and predictable components. The predictable component of BSV (termed BSVP) is explained by covariates, individual characteristics e.g. weight. As BSVP increases, the remaining unpredictable (or random) between subject variability (BSVR) decreases since BSV = BSVP + BSVR, and BSV is a constant in any given data set. Since BSV and BSVR are estimated from the base and full covariate models, respectively, then BSVP = BSV-BSVR. The aim of this study was to explore the hypothesis, that a significant covariate may not always decrease BSVR. The specific aims were: (1) to explore circumstances where BSVR may not be reduced when adding a significantly correlated covariate and (2) to explore whether specific models for covariates may eliminate this anomaly when assessing BSVR. Simulations were performed using MATLAB (2011a) and estimation using NONMEM (ver 7.2) with FOCE and INTERACTION. A 1-compartment intravenous bolus PK model was used for simulation following a single unit dose (d = 1). The BSV of clearance [BSV(CL)] was described according to a log-normal distribution model with mean zero and variance ω². An additive random unexplained variability was assumed. Initially, we show through a simple simulation that BSVR can increase when a significantly correlated covariate is added to the model. We follow this with five simulation scenarios, A to E, that have various levels of correlation between the continuous covariate (Z) and CL ranging from 0 to 100 %. Each simulated scenario was replicated 100 times and estimated by a base model (i.e. without covariate addition) and six covariate models (M1-M6) which included non-nested (M1), nested (M2), and two types of interaction models for each of M1 and M2; non-nested interaction (M3, M5), nested interaction (M4, M6). Initially, through a motivating example we show that BSVR may not reduce even when there is 50 % correlation between the covariate Z and CL. It was found that with 0 % correlation M1, the non-nested covariate model (NNCM) resulted in negative BSVP (inflated BSVR) whereas M2, the nested covariate model (NCM), resulted in a calculated BSVP of zero. NNCM (M1) shows negative BSVP (BSVR > BSV) with correlation as high as 50 % and this model needs a minimum of 75 % correlation to show a positive BSVP. NCM (M2) shows positive but downwardly biased BSVP with 25, 50 and 75 % correlations. However, inclusion of a covariate-eta interaction term for both types of covariate models resulted in greater BSVP for 25, 50 and 75 % correlation scenarios compared to NNCM and NCM respectively. For 100 % correlation, it was found that covariate-eta interaction models show the same BSVP as the models without the interaction term, i.e. under perfect positive correlation all models perform similarly and correctly. It was found that a significantly correlated covariate may not reduce BSVR and in fact it may inflate the BSVR due to statistical misspecification of the covariate model. Incorporating statistical models that account for the covariate-eta interaction may be useful diagnostically in identifying the variability explained by covariates.

Entities:  

Mesh:

Year:  2012        PMID: 22767340     DOI: 10.1007/s10928-012-9256-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

1.  Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.

Authors:  Jakob Ribbing; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

Review 2.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

3.  Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 4.  Population clinical pharmacology of children: modelling covariate effects.

Authors:  Brian J Anderson; Karel Allegaert; Nicholas H G Holford
Journal:  Eur J Pediatr       Date:  2006-06-29       Impact factor: 3.183

Review 5.  Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Authors:  C Dartois; K Brendel; E Comets; C M Laffont; C Laveille; B Tranchand; F Mentré; A Lemenuel-Diot; P Girard
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

6.  Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age.

Authors:  Lin Lin; Jian-Wei Zhang; Yue Huang; Jie Bai; Mei-Hua Cai; Ma-Zhong Zhang
Journal:  Paediatr Anaesth       Date:  2011-09-15       Impact factor: 2.556

7.  Development of a dosing strategy for enoxaparin in obese patients.

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

8.  Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.

Authors:  Ivan Matthews; Carl Kirkpatrick; Nicholas Holford
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

  8 in total
  2 in total

1.  Concordance between criteria for covariate model building.

Authors:  Stefanie Hennig; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-06       Impact factor: 2.745

2.  Why we should sample sparsely and aim for a higher target: Lessons from model-based therapeutic drug monitoring of vancomycin in intensive care patients.

Authors:  Tingjie Guo; Reinier M van Hest; Lucas M Fleuren; Luca F Roggeveen; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Johan G C van Hasselt; Paul W G Elbers
Journal:  Br J Clin Pharmacol       Date:  2020-08-17       Impact factor: 3.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.